RAD51 and lung carcinoma: The increase of RBE in both cell lines upon ganetespib treatment closely resembles previously described RBE differences in HRR-deficient lung cancer cells compared to HRR-proficient cell lines [19] and as demonstrated by siRNA-mediated knockdown of Rad51 in A549 and CHO cells [16, 17].